Eli Lilly’s daily GLP-1 pill shows strong weight loss results without food restrictions

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers.